CMTM4 and neoplasm: Indeed, we found that CMTM4 KD tumor was more responsive to PD-L1 antibodies treatment (Fig. 7D), which is resulted from reduced inflammatory cytokines productions from CMTM4 KD cells (Fig. 6) with retarded EGFR signaling (Fig. 3).